Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma-Reference-Cited by-同舟云学术

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Published:2018-05-03 Issue:12 Volume:124 Page:2561-2569
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Romaguera Jorge E.¹^ORCID,Wang Michael¹^ORCID,Feng Lei²,Fayad Luis E.¹,Hagemeister Frederick¹,McLaughlin Peter¹,Rodriguez M. Alma¹,Fanale Michelle¹,Orlowski Robert¹,Kwak Larry W.³,Neelapu Sattva¹,Oki Yasuhiro¹,Pro Barbara¹,Younes Anas⁴,Samaniego Felipe¹,Fowler Nathan¹,Hartig Kimberly¹,Valentinetti Marisa⁵,Smith Judy⁵,Ford Peggy⁵,Naig Adam¹,Medeiros L. Jeffrey⁶,Kantarjian Hagop M.⁷^ORCID,Goy Andre⁵

Affiliation:

1. Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Lymphoma Center, City of Hope; Duarte California

4. Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York New York

5. Lymphoma Division; John Theurer Cancer Hackensack University Medical Center; Hackensack New Jersey

6. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

7. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

University of Texas MD Anderson Cancer Center

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center;Chihara;Br J Haematol.,2016

2. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau;Eskelund;Br J Haematol.,2016

3. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma;Fisher;J Clin Oncol.,2006

4. Combined targeting of the proteasome and Bcl-2 sensitizes human B-cell lymphoma and multiple myeloma to cyclophosphamide in vitro and in vivo models of these diseases [abstract 2484];O'Connor;Blood.,2004

5. Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells [abstract 1387];Goy;Blood.,2004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

2. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments;American Journal of Hematology;2022-04-05

4. Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma;Expert Review of Hematology;2021-09-17

5. Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma;Acta Biomaterialia;2021-01